---
schema_version: "secwatch.filing_event.v1"
accession: "0001193125-22-273358"
form_type: "8-K"
ticker: "CERO"
cik: "0001870404"
company_name: "CERO THERAPEUTICS HOLDINGS, INC."
filed_at: "2022-10-31T23:59:59+00:00"
generated_at: "2026-06-22T21:57:13.009052+00:00"
event_type: "m_and_a"
sentiment: "neutral"
materiality_score: 0.8
calibrated_materiality_score: 0.8
confidence: "high"
source: SEC EDGAR
---

# Phoenix Biotech SPAC to merge with Intrinsic Medicine in all-stock deal

## Summary
- Consideration: 13.6M shares of Class A common stock to Intrinsic equity holders.
- Intrinsic is a preclinical-stage therapeutics company using synthetic biology to develop human milk oligosaccharide medicines.
- Closing requires at least $15M available cash (trust + PIPE), Nasdaq listing, and stockholder approvals.
- Sponsor and key Intrinsic stockholders agree to vote in favor; lock-up 180 days or $12.50 price trigger.
- Post-combination company to be led by executives Martinez, Ferrone, Chuang, and Crawford.

## SEC filing metadata
- accession: 0001193125-22-273358
- form_type: 8-K
- ticker: CERO
- cik: 0001870404
- company_name: CERO THERAPEUTICS HOLDINGS, INC.
- filed_at: 2022-10-31T23:59:59+00:00
- event_type: m_and_a
- sentiment: neutral
- materiality_score: 0.8
- calibrated_materiality_score: 0.8
- confidence: high
- sec_items: 1.01, 7.01, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1870404/000119312522273358/0001193125-22-273358-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1870404/000119312522273358/d417140d8k.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001193125-22-273358
- JSON: https://secwatch.observer/filing/0001193125-22-273358.json
- Plain text: https://secwatch.observer/filing/0001193125-22-273358.txt

## Key facts
- Material Agreements
  CERO THERAPEUTICS HOLDINGS, INC. entered into Business Combination Agreement with OM Merger Sub, Inc., Intrinsic Medicine, Inc. (effective 2022-10-30).
  - Action: entry
  - Agreement: merger
  - Counterparty: OM Merger Sub, Inc., Intrinsic Medicine, Inc.
  - Effective: 2022-10-30
  source text: On October 30, 2022, Phoenix Biotech Acquisition Corp., a Delaware corporation (the “ Company ”), entered into a business combination agreement (the “ Business Combination Agreement ”) by and among the Company, OM Merger Sub, Inc., a Delaware corporation (“ Merger Sub ”), and Intrinsic Medicine, Inc., a Delaware corporation (“ Intrinsic ”).
  evidence_url: https://www.sec.gov/Archives/edgar/data/1870404/000119312522273358/0001193125-22-273358-index.htm

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.